Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 4/2024

23-02-2024 | Breast Cancer | REVIEW

Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?

Authors: Ilana Schlam, Joshua Dower, Filipa Lynce

Published in: Current Oncology Reports | Issue 4/2024

Login to get access

Abstract

Purpose of review

To summarize the treatment strategies for patients with human epidermal growth factor receptor 2 (HER2)-positive disease and triple-negative breast cancer (TNBC) who have residual disease after preoperative systemic therapy.

Recent findings

There has been a shift towards neoadjuvant systemic therapy for selected patients with HER2-positive and TNBC. Assessing the tumor’s response to therapy provides prognostic information and allows individualization of the postoperative treatment for these patients based on the tumor response to neoadjuvant therapy. Patients with TNBC with residual disease after neoadjuvant therapy can be treated with pembrolizumab, capecitabine, or olaparib. Those with HER2-positive disease are treated with adjuvant trastuzumab emtansine.

Summary

The treatment of early breast cancer has evolved significantly, and patient outcomes continue to improve. As better treatments are developed, we will need biomarkers to determine which patients may benefit from certain therapies to continue to improve outcomes by right-sizing treatments and limiting toxicities.
Literature
1.
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA: A Cancer J Clin. 2023;73(1):17–48.
2.
3.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39.CrossRef
4.
••Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72. Validated correlation between pCR and better long-term outcomes in patients with breast cancer.CrossRefPubMed
5.
••Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59. Role of capecitabine in patients with residual disease and TNBC.CrossRefPubMed
6.
••von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–28. Initial findings of TDM1 in HER2+ breast cancer with residual disease.CrossRef
7.
••Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382(9):810–21. Role of pembrolizumab in patients with residual disease and TNBC.CrossRefPubMed
8.
Swain SM, Macharia H, Cortes J, et al. Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis. Cancers (Basel). 2022;14(20):5051.
9.
Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–22.CrossRefPubMed
10.
•Pusztai L, Denkert C, O’Shaughnessy J, et al. Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC exploratory analysis from KEYNOTE-522. J Clin Oncol. 2022;40(16_suppl):503–503. Reported use of RBC in early TNBC and how it can be used to predict long-term outcomes.CrossRef
11.
Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–60.CrossRefPubMed
12.
•Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556–67. Provided information about long-term outcomes for patients with TNBC treated with pembrolizumab.CrossRefPubMed
13.
Schmid P, Cortes J, Dent R, et al. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: updated event-free survival results from the phase 3 KEYNOTE-522 study. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 2023.
14.
•Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials—USOR 06–090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647–55. This analysis revealed which patients benefit from anthracycline-containing therapies.CrossRefPubMedPubMedCentral
15.
••Mayer IA, Zhao F, Arteaga CL, et al. Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131. J Clin Oncol. 2021;39(23):2539–51. Provided additional information about the role of adjuvant capectiabine in TNBC.CrossRefPubMedPubMedCentral
16.
Shah AN, Flaum L, Helenowski I, et al. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer. J Immunother Cancer. 2020;8(1):e000173.
17.
•Lynce F, Mainor C, Geng X, et al. Abtract PD9–02: Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): the OXEL study. Cancer Res. 2022;82(4_Supplement):PD9-02-PD9-02. ctDNA use in patients with residual disease after neoadjuvant chemotherapy for TNBC.CrossRef
18.
Breast Cancer Association Consortium, Dorling L, Carvalho S, et al. Breast cancer risk genes — association analysis in more than 113,000 women. N Engl J Med. 2021;384(5):428–39.CrossRef
19.
Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–33.CrossRefPubMed
20.
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753–63.CrossRefPubMedPubMedCentral
21.
••Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–405. Role of adjuvant olaparib in TNBC.CrossRefPubMedPubMedCentral
22.
Marmé F, Solbach C, Michel L, et al. Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer. 2021;153:203–12.CrossRefPubMed
23.
Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020;21(9):1155–64.CrossRefPubMed
24.
Wanderley CWS, Correa TS, Scaranti M, et al. Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications. Front Immunol. 2022;13:816642.CrossRefPubMedPubMedCentral
25.
Fanucci KA, Pilat MJ, Shyr D, et al. Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer an open-label, multicenter, randomized phase II trial. Cancer Res. 2023;83(8_Supplement):CT145.CrossRef
26.
Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16(1):87–97.CrossRefPubMed
27.
van der Noll R, Ang JE, Jager A, et al. Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors [abstract]. J Clin Oncol. 2013;31(15_suppl):Abstract 2579.CrossRef
28.
Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–68.CrossRefPubMed
29.
Miller K, Tong Y, Jones DR, et al. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer final efficacy results of Hoosier Oncology Group BRE09–146. J Clin Oncol. 2015;33(15_suppl):1082–1082.CrossRef
30.
Lynce F, Shimada K, Geng X, et al. Abstract CT142: TALAVE: Induction talazoparib (tala) followed by combined tala and avelumab in patients (pts) with advanced breast cancer (ABC). Cancer Res. 2023;83(8_Supplement):CT142.CrossRef
31.
Veneris JT, Matulonis UA, Liu JF, et al. Choosing wisely: selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol Oncol. 2020;156(2):488–97.CrossRefPubMed
32.
van der Voort A, van Ramshorst MS, van Werkhoven ED, et al. Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast cancer: a secondary analysis of the TRAIN-2 randomized, phase 3 trial. JAMA Oncol. 2021;7(7):978–84.CrossRefPubMed
33.
Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.CrossRefPubMed
34.
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.CrossRefPubMed
35.
•Loibl S, Jassem J, Sonnenblick A, et al. VP6–2022: adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY 8.4 years’ follow-up. Ann Oncol. 2022;33(9):986–7. Long-term data about the role of pertuzumab in HER2-positive breast cancer.CrossRef
36.
Weiss A, Martínez-Sáez O, Waks AG, et al. Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor-positive breast cancer: results from two international cohorts. Cancer. 2023;129(12):1836–45.CrossRefPubMed
37.
••Loibl SMM, Untch M, Huang CS, et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: KATHERINE final IDFS and updated OS analysis. Presented at the San Antonio Breast Cancer Symposium, San Antonio, TX, December 2023. In this abstract, the authors presented long-term data of the KATHERINE trial showing that at 8 years of follow up, patients treated with TDM1 had better outcomes.
38.
Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387(3):217–26.CrossRefPubMed
39.
40.
Barcenas CH, Hurvitz SA, Di Palma JA, et al. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Ann Oncol. 2020;31(9):1223–30.CrossRefPubMed
41.
Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2019;382(7):597–609.CrossRefPubMed
42.
Cortés J, Kim S-B, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54.CrossRefPubMed
43.
Turner NC, Swift C, Jenkins B, et al. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Ann Oncol. 2023;34(2):200–11.CrossRefPubMed
44.
Metadata
Title
Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
Authors
Ilana Schlam
Joshua Dower
Filipa Lynce
Publication date
23-02-2024
Publisher
Springer US
Published in
Current Oncology Reports / Issue 4/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01501-0

Other articles of this Issue 4/2024

Current Oncology Reports 4/2024 Go to the issue

REVIEW

Metronomic Chemotherapy in Elderly Patients

REVIEW

Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma

REVIEW

Cerebrospinal Fluid Liquid Biopsies in the Evaluation of Adult Gliomas

REVIEW

Update on the management of bone metastases

REVIEW

Lymph node dissection in testicular cancer

REVIEW

Oral Complications and Management Strategies for Cancer Patients: Principles of Supportive Oncology in Dentistry
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits